Literature DB >> 10493930

Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

P O Falnes1, R Welker, H G Kräusslich, S Olsnes.   

Abstract

Diphtheria toxin enters the cytosol of mammalian cells where it inhibits cellular protein synthesis, leading to cell death. Recently we found that the addition of a signal for N-end-rule-mediated protein degradation to diphtheria toxin substantially reduced its intracellular stability and toxicity. These results prompted us to construct a toxin containing a degradation signal that is removable through the action of a viral protease. In principle, such a toxin would be preferentially stabilized, and thus activated, in cells expressing the viral protease in the cytosol, i.e. virus-infected cells, thereby providing a specific eradication of these cells. In the present work we describe the construction of toxins that contain a signal for N-end-rule-mediated degradation just upstream of a cleavage site for the protease from HIV type 1 (HIV-1 PR). We show that the toxins are cleaved by HIV-1 PR exclusively at the introduced sites, and thereby are converted from unstable to stable proteins. Furthermore, this cleavage substantially increased the ability of the toxins to inhibit cellular protein synthesis. However, the toxins were unable to selectively eradicate HIV-1-infected cells, apparently due to low cytosolic HIV-1 PR activity, since we could not detect cleavage of the toxins by HIV-1 PR in infected cells. Alternative strategies for the construction of toxins that can specifically be activated by viral proteases are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493930      PMCID: PMC1220542     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

Review 2.  Rationale for the use of immunotoxins in the treatment of HIV-infected humans.

Authors:  M G Van Oijen; F W Preijers
Journal:  J Drug Target       Date:  1998       Impact factor: 5.121

Review 3.  The N-end rule.

Authors:  A Varshavsky
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1995

4.  [Self-inhibiting N-glycosidase activity of shigella toxin].

Authors:  A N Polesskaia; O Garred; S Olsnes; Iu V Kozlov
Journal:  Mol Biol (Mosk)       Date:  1997 May-Jun

5.  Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Authors:  N S Duesbery; C P Webb; S H Leppla; V M Gordon; K R Klimpel; T D Copeland; N G Ahn; M K Oskarsson; K Fukasawa; K D Paull; G F Vande Woude
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

6.  One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell.

Authors:  M Yamaizumi; E Mekada; T Uchida; Y Okada
Journal:  Cell       Date:  1978-09       Impact factor: 41.582

7.  Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein.

Authors:  A M Vocero-Akbani; N V Heyden; N A Lissy; L Ratner; S F Dowdy
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

8.  Characterization of membrane translocation by anthrax protective antigen.

Authors:  J Wesche; J L Elliott; P O Falnes; S Olsnes; R J Collier
Journal:  Biochemistry       Date:  1998-11-10       Impact factor: 3.162

9.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.

Authors:  A G Tomasselli; J O Hui; T K Sawyer; D J Staples; C Bannow; I M Reardon; W J Howe; D L DeCamp; C S Craik; R L Heinrikson
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.486

View more
  5 in total

Review 1.  The N-end rule pathway and regulation by proteolysis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2011-08       Impact factor: 6.725

2.  Design and characterization of an HIV-specific ribonuclease zymogen.

Authors:  Rebecca F Turcotte; Ronald T Raines
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

3.  Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.

Authors:  Assaf Shapira; Meital Gal-Tanamy; Limor Nahary; Dana Litvak-Greenfeld; Romy Zemel; Ran Tur-Kaspa; Itai Benhar
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

Review 4.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

5.  Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin.

Authors:  Assaf Shapira; Shiran Shapira; Meital Gal-Tanamy; Romy Zemel; Ran Tur-Kaspa; Itai Benhar
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.